Annotation Detail
Information
- Associated Genes
- ABL1
- Associated Variants
-
ABL1 MUTATION
ABL1 MUTATION - Associated Disease
- chronic myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysis at baseline, subsets were evaluated for complete hematologic response (CHR) and major cytogenetic response (MCyR). Both were comparable for patients with Abl1 mutation versus without [CHR = 33/34 vs. 27/27; MCyR = 41/59 (69%) vs. 19/35 (54%)]. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6335
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2371
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Chronic Myeloid Leukemia
- Evidence Direction
- Does Not Support
- Drug
- Bosutinib
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 21865346
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Bosutinib | Resitance or Non-Reponse | false |